Literature DB >> 16959828

Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease.

Keith C Norris1, Tom Greene, Joel Kopple, Janice Lea, Julia Lewis, Mike Lipkowitz, Pete Miller, Annie Richardson, Stephen Rostand, Xuelei Wang, Lawrence J Appel.   

Abstract

Patients with chronic kidney disease have an increased risk for progression to ESRD. The purpose of this study was to examine factors that predict increased risk for adverse renal outcomes. Cox regression was performed to assess the potential of 38 baseline risk factors to predict the clinical renal composite outcome of 50% or 25-ml/min per 1.73 m(2) GFR decline or ESRD among 1094 black patients with hypertensive nephrosclerosis (GFR 20 to 65 ml/min per 1.73 m(2)). Patients were trial participants who had been randomly assigned to one of two BP goals and to one of three antihypertensive regimens and followed for a range of 3 to 6.4 yr. In unadjusted and adjusted analyses, baseline proteinuria was consistently associated with an increased risk for adverse renal outcomes, even at low levels of proteinuria. The relationship of proteinuria with adverse renal outcomes also was evident in analyses that were stratified by level of GFR, which itself was associated with adverse renal outcomes but only at levels <40 ml/min. Other factors that were significantly associated with increased renal events after adjustment for baseline GFR, age, and gender, both with and without adjustment for baseline proteinuria, included serum creatinine, urea nitrogen, and phosphorus. In black patients with hypertensive nephrosclerosis, increased proteinuria, reduced GFR, and elevated levels of serum creatinine, urea nitrogen and phosphorus were directly associated with adverse clinical renal events. These findings identify a subset of this high-risk population that might benefit from even more aggressive treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959828      PMCID: PMC3833081          DOI: 10.1681/ASN.2005101101

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  39 in total

1.  Comorbidity and its change predict survival in incident dialysis patients.

Authors:  Dana C Miskulin; Klemens B Meyer; Alice A Martin; Nancy E Fink; Josef Coresh; Neil R Powe; Michael J Klag; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

2.  To have and have not: Health and health care disparities in chronic kidney disease.

Authors:  Neil R Powe
Journal:  Kidney Int       Date:  2003-08       Impact factor: 10.612

3.  Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity.

Authors:  Frank Stam; Coen van Guldener; Casper G Schalkwijk; Piet M ter Wee; Ab J M Donker; Coen D A Stehouwer
Journal:  Nephrol Dial Transplant       Date:  2003-05       Impact factor: 5.992

Review 4.  Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.

Authors:  Adeera Levin
Journal:  Semin Dial       Date:  2003 Mar-Apr       Impact factor: 3.455

5.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.

Authors:  Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

Review 6.  Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.

Authors:  Allan J Collins
Journal:  Nephrol Dial Transplant       Date:  2003-06       Impact factor: 5.992

Review 7.  Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Gladys Block; Michael H Humphreys; Joel D Kopple
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

8.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Authors:  William F Keane; Barry M Brenner; Dick de Zeeuw; Jean-Pierre Grunfeld; Janet McGill; William E Mitch; Artur B Ribeiro; Shahnaz Shahinfar; Roger L Simpson; Steven M Snapinn; Robert Toto
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

9.  Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.

Authors:  Temduang Chuahirun; Apurv Khanna; Kay Kimball; Donald E Wesson
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

10.  High prevalence of target organ damage in young, African American inner-city men with hypertension.

Authors:  Wendy S Post; Martha N Hill; Cheryl R Dennison; James L Weiss; Gary Gerstenblith; Roger S Blumenthal
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jan-Feb       Impact factor: 3.738

View more
  55 in total

1.  Sex-Related Disparities in CKD Progression.

Authors:  Ana C Ricardo; Wei Yang; Daohang Sha; Lawrence J Appel; Jing Chen; Marie Krousel-Wood; Anjella Manoharan; Susan Steigerwalt; Jackson Wright; Mahboob Rahman; Sylvia E Rosas; Milda Saunders; Kumar Sharma; Martha L Daviglus; James P Lash
Journal:  J Am Soc Nephrol       Date:  2018-12-03       Impact factor: 10.121

Review 2.  Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?

Authors:  Michael R Lattanzio; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

3.  Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.

Authors:  Csaba P Kovesdy; Olga Kuchmak; Jun Ling Lu; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2010-08-21       Impact factor: 8.860

4.  Longitudinal progression trajectory of GFR among patients with CKD.

Authors:  Liang Li; Brad C Astor; Julia Lewis; Bo Hu; Lawrence J Appel; Michael S Lipkowitz; Robert D Toto; Xuelei Wang; Jackson T Wright; Tom H Greene
Journal:  Am J Kidney Dis       Date:  2012-01-26       Impact factor: 8.860

5.  Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.

Authors:  Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

6.  CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Authors:  Vibha Bhatnagar; Erin P Garcia; Daniel T O'Connor; Victoria H Brophy; John Alcaraz; Erin Richard; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  Am J Nephrol       Date:  2009-11-12       Impact factor: 3.754

7.  Mineral metabolites and CKD progression in African Americans.

Authors:  Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

8.  Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Authors:  Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-25       Impact factor: 8.237

9.  No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Authors:  Rajnish Mehrotra; Carmen A Peralta; Shu-Cheng Chen; Suying Li; Michael Sachs; Anuja Shah; Keith Norris; Georges Saab; Adam Whaley-Connell; Bryan Kestenbaum; Peter A McCullough
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

10.  A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease.

Authors:  Paul E Drawz; Puja Goswami; Reem Azem; Denise C Babineau; Mahboob Rahman
Journal:  J Am Geriatr Soc       Date:  2013-04-25       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.